Professor Jacob Sherkow spoke to Law360 about the advantages Pfizer and Moderna may have over other pharmaceutical companies for future vaccine development, should they win broad patent protection for their COVID-19 vaccines. 

"Prior to the development of their vaccines, [mRNA] was a completely untested, unchartered mechanism of action for a vaccine, so it seems like Moderna and Pfizer are on track to get a bunch of pretty broad patents covering mRNA vaccines generally," he said. "Some of the intellectual property foundations that are being laid now are going to play an increasingly important role with respect to the development of vaccines in the future."

Read the full article at law360.com.